Evidence map›Paper›PMID 37443710›Full record

ReviewCells2023

Multilineage Differentiating Stress Enduring (Muse) Cells: A New Era of Stem Cell-Based Therapy.

Raghad F Alanazi, Basma S Alhwity, Raghad M Almahlawi, Bashayer D Alatawi, Shatha A Albalawi, Raneem A Albalawi, Amaal A Albalawi, Mohamed S Abdel-Maksoud, Nehal Elsherbiny

Registry-linked trialOpen access · goldAbstract readReview
In one paragraph

Review in Cells, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07511660 (Prospective Single Arm Observational Cohort Study of Ultrasound Guided Intra Ovarian Injection of Muse Cells), which is not on this map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
8.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07511660 enrolling by invitationnot on this mapstarted 2026, after this paper: background citation

Prospective Single Arm Observational Cohort Study of Ultrasound Guided Intra Ovarian Injection of Muse Cells (Multilineage Differentiating Stress-Enduring Cells) for Reversal of Perimenopausal Ovarian Decline in Women Aged 28-70 Years

Typeobservational_patient_registrySponsorHealing Hope InternationalRan2026 to 2030Enrolled12ConditionsPerimenopause, Perimenopause-Related Depression, Premature Ovarian Insufficiency, Premature Ovarian Failure (POF)
3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. To Repair a Broken Heart: Stem Cells in Ischemic Heart Disease.Current issues in molecular biology · 2024
    Review
  18. Frontiers in cell and developmental biology · 2024
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Raghad F AlanaziPharm D Program, Faculty of Pharmacy, University of Tabuk, Tabuk 71491, Saudi Arabia.
Basma S AlhwityPharm D Program, Faculty of Pharmacy, University of Tabuk, Tabuk 71491, Saudi Arabia.
Raghad M AlmahlawiPharm D Program, Faculty of Pharmacy, University of Tabuk, Tabuk 71491, Saudi Arabia.
Bashayer D AlatawiPharm D Program, Faculty of Pharmacy, University of Tabuk, Tabuk 71491, Saudi Arabia.
Shatha A AlbalawiPharm D Program, Faculty of Pharmacy, University of Tabuk, Tabuk 71491, Saudi Arabia.ORCID 0009-0004-8009-3135
Raneem A AlbalawiPharm D Program, Faculty of Pharmacy, University of Tabuk, Tabuk 71491, Saudi Arabia.
Amaal A AlbalawiPharm D Program, Faculty of Pharmacy, University of Tabuk, Tabuk 71491, Saudi Arabia.
Mohamed S Abdel-MaksoudDepartment of Pharmacology & Toxicology, Faculty of Pharmacy, University of Tabuk, Tabuk 71491, Saudi Arabia.
Nehal ElsherbinyDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Tabuk, Tabuk 71491, Saudi Arabia.
University of Tabuk · SAMansoura University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Stem cell transplantation has recently demonstrated a significant therapeutic efficacy in various diseases. Multilineage-differentiating stress-enduring (Muse) cells are stress-tolerant endogenous pluripotent stem cells that were first reported in 2010. Muse cells can be found in the peripheral blood, bone marrow and connective tissue of nearly all body organs. Under basal conditions, they constantly move from the bone marrow to peripheral blood to supply various body organs. However, this rate greatly changes even within the same individual based on physical status and the presence of injury or illness. Muse cells can differentiate into all three-germ-layers, producing tissue-compatible cells with few errors, minimal immune rejection and without forming teratomas. They can also endure hostile environments, supporting their survival in damaged/injured tissues. Additionally, Muse cells express receptors for sphingosine-1-phosphate (S1P), which is a protein produced by damaged/injured tissues. Through the S1P-S1PR2 axis, circulating Muse cells can preferentially migrate to damaged sites following transplantation. In addition, Muse cells possess a unique immune privilege system, facilitating their use without the need for long-term immunosuppressant treatment or human leucocyte antigen matching. Moreover, they exhibit anti-inflammatory, anti-apoptotic and tissue-protective effects. These characteristics circumvent all challenges experienced with mesenchymal stem cells and induced pluripotent stem cells and encourage the wide application of Muse cells in clinical practice. Indeed, Muse cells have the potential to break through the limitations of current cell-based therapies, and many clinical trials have been conducted, applying intravenously administered Muse cells in stroke, myocardial infarction, neurological disorders and acute respiratory distress syndrome (ARDS) related to novel coronavirus (SARS-CoV-2) infection. Herein, we aim to highlight the unique biological properties of Muse cells and to elucidate the advantageous difference between Muse cells and other types of stem cells. Finally, we shed light on their current therapeutic applications and the major obstacles to their clinical implementation from laboratory to clinic.

Indexed as

COVID-19Pluripotent Stem CellsAlprostadilCell DifferentiationHumansSARS-CoV-2Stem Cell TransplantationAlprostadilapplicationsclinical trialsmuse cellsunique characteristics

Identifiers

PMID37443710
PMCPMC10340735
OpenAlexW4381663459

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.